Monoclonal antibody · Antagonist of ErbB3 (HER3) receptor (ERBB3) · developed by Celldex Therapeutics
CDX-3379 is a human monoclonal antibody that binds a unique epitope on the ErbB3 (HER3) receptor, a member of the EGFR family of receptor tyrosine kinases. It prevents ErbB3 phosphorylation and both ligand-dependent and ligand-independent signaling, inhibiting proliferation and survival of ErbB3-expressing tumor cells. It is studied in head and neck squamous cell carcinoma and melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03580382 | Phase 1/2 | Melanoma | Terminated | CLDX |
| NCT03254927 | Phase 2 | Advanced Head and Neck Squamous Cell Carcinoma | Terminated | CLDX |
| NCT02473731 | Phase 1 | Squamous Cell Carcinoma of the Head and Neck | Completed | CLDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Head and Neck Squamous Cell CarcinomaMelanomaSquamous Cell Carcinoma of the Head and Neck
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.
See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLDX catalysts and pipeline →